Barclays Maintains Overweight on Ultragenyx Pharmaceutical, Raises Price Target to $35
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsPrice Target
Barclays analyst Eliana Merle maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Overweight and raises the price target from $32 to $35.
Barclays analyst Eliana Merle maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Overweight and raises the price target from $32 to $35.